Recurrent Hepatitis C in Liver Allografts: Prospective Assessment of Diagnostic Accuracy, Identification of Pitfalls, and Observations about Pathogenesis

American Journal of Surgical Pathology

Volumn 28, Issue 5, 2004, Pages 658-669

  Demetris, A J ^a   Eghtesad, B ^a   Marcos, A ^a   Ruppert, K ^b   Nalesnik, M A ^a   Randhawa, P ^a   Wu, T ^a   Krasinskas, A ^a   Fontes, P ^a   Cacciarelli, T ^a   Shakil, A O ^c   Murase, N ^a   Fung, J J ^a   Starzl, T E ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Acute and chronic rejection; Banff schema; Liver allograft; Recurrent hepatitis; Tolerance

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN; STEROID; TACROLIMUS; VIRUS RNA;

ACUTE GRAFT REJECTION; ADULT; AGED; ALLOGRAFT; ARTICLE; CHOLESTASIS; CHRONIC GRAFT REJECTION; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DISEASE SEVERITY; FEMALE; GRAFT REJECTION; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LIVER BIOPSY; LIVER GRAFT; LIVER INJURY; MALE; PATHOGENESIS; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; RECURRENT INFECTION; RETROSPECTIVE STUDY; RNA ANALYSIS;

EID: 2342581551     PISSN: 01475185     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000478-200405000-00015     Document Type: Article

References (42)

1. Abraczinskas DR, Chung RT. Allograft dysfunction and hyperbilirubinemia in a liver transplant recipient. Transpl Infect Dis. 2000;2:186-193.
2. Amati L, Caradonna L, et al. Modifications of the immune responsiveness in patients with hepatitis C virus infection following treatment with IFN-alpha/ribavirin. Curr Pharm Des. 2002;8:981-993.
3. Anonymous. Banff schema for grading liver allograft rejection: an international consensus document. Hepatology. 1997;25:658-663.
4. Auffermann-Gretzinger S, Keeffe EB, et al. Impaired dendritic cell maturation in patients with chronic, but not resolved, hepatitis C virus infection. Blood. 2001;97:3171-3176.
5. Baiocchi L, Tisone G, et al. Hepatic steatosis: a specific sign of hepatitis C reinfection after liver transplantation. Liver Transpl Surg. 1998;4:441-447.
6. Berenguer M. Natural history of recurrent hepatitis C. Liver Transpl. 2002;8(suppl 1):14-18.
7. Berenguer M, Crippin J, et al. A model to predict severe HCV-related disease following liver transplantation. Hepatology. 2003;38:34-41.
8. Blakolmer K, Seaberg EC, et al. Analysis of the reversibility of chronic liver allograft rejection implications for a staging schema. Am J Surg Pathol. 1999;23:1328-1339.
9. Brillanti S, Vivarelli M, et al. Slowly tapering off steroids protects the graft against hepatitis C recurrence after liver transplantation. Liver Transpl. 2002;8:884-888.
10. Chang KM. Immunopathogenesis of hepatitis C virus infection. Clin Liver Dis. 2003;7:89-105.
11. Charlton M, Seaberg E, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology. 1998;28:823-830.
12. Demetris A, Adams D, et al. Update of the International Banff Schema for Liver Allograft Rejection: working recommendations for the histopathologic staging and reporting of chronic rejection. An International Panel. Hepatology. 2000;31:792-799.
13. Demetris AJ, Jaffe R, et al. Recurrent hepatitis B in liver allograft recipients: differentiation between viral hepatitis B and rejection. Am J Pathol. 1986;125:161-172.
14. Demetris AJ, Murase N, et al. Dendritic cells in rejection and acceptance of solid organ allografts. In: Lotze MT, Thomson A, eds. Dendritic Cells. San Diego: Academic Press; 2001:439-458.
15. Demetris AJ, Ruppert K, et al. Real-time monitoring of acute liver-allograft rejection using the Banff schema. Transplantation. 2002;74:1290-1296.
16. Demetris AJ, Todo S, et al. Evolution of hepatitis B virus liver disease after hepatic replacement: practical and theoretical considerations. Am J Pathol. 1990;137:667-676.
17. Gardner JP, Durso RJ, et al. L-SIGN (CD 209L) is a liver-specific capture receptor for hepatitis C virus. Proc Natl Acad Sci USA. 2003;100:4498-4503.
18. Ghobrial RM. Retransplantation for recurrent hepatitis C. Liver Transpl. 2002;8(suppl 1):38-43.
19. Gottschlich MJ, Aardema KL, et al. The use of hepatitis C viral RNA levels in liver tissue to distinguish rejection from recurrent hepatitis C. Liver Transpl. 2001;7:436-441.
20. Hayashi M, Martinez OM, et al. Expression of cytokines and immune mediators during chronic liver allograft rejection. Transplantation. 1995;60:1533-1538.
21. Isaguliants MG. Hepatitis C virus clearance: the enigma of failure despite an impeccable survival strategy. Curr Pharm Biotechnol. 2003;4:169-183.
22. Isaguliants MG, Ozeretskovskaya NN. Host background factors contributing to hepatitis C virus clearance. Curr Pharm Biotechnol. 2003;4:185-193.
23. Kanto T, Hayashi N, et al. Impaired allostimulatory capacity of peripheral blood dendritic cells recovered from hepatitis C virus-infected individuals. J Immunol. 1999;162:5584-5591.
24. Layden TJ, Layden JE, et al. Mathematical modeling of viral kinetics: a tool to understand and optimize therapy. Clin Liver Dis. 2003;7:163-178.
25. Leung JY, Abraczinskas DR, et al. Recurrent allograft HCV presenting as acute cellular rejection: successful management with interferon and ribavirin alone. Clin Transplant. 2003;17:275-283.
26. Lunz JG 3rd, Contrucci S, et al. Replicative senescence of biliary epithelial cells precedes bile duct loss in chronic liver allograft rejection: increased expression of p21(WAF1/Cip1) as a disease marker and the influence of immunosuppressive drugs. Am J Pathol 2001;158:1379-1390.
27. Mateo R, Demetris A, et al. Early detection of de novo hepatitis C infection in patients after liver transplantation by reverse transcriptase polymerase chain reaction. Surgery. 1993;114:442-448.
28. McCaughan GW, Zekry A. Pathogenesis of hepatitis C virus recurrence in the liver allograft. Liver Transpl. 2002;8(suppl 1):7-13.
29. Okuda T, Ishikawa T, et al. Early passenger leukocyte migration and acute immune reactions in the rat recipient spleen during liver engraftment: with particular emphasis on donor major histocompatibility complex class II+ cells. Transplantation. 2002;74:103-111.
30. Papatheodoridis GV, Davies S, et al. The role of different immunosuppression in the long-term histological outcome of HCV reinfection after liver transplantation for HCV cirrhosis. Transplantation. 2001;72:412-418.
31. Randhawa PS, Demetris AJ. Hepatitis C virus infection in liver allografts. Pathol Annu. 1995;30:203-226.
32. Rosen HR. Hepatitis C virus in the human liver transplantation model. Clin Liver Dis. 2003;7:107-125.
33. Saxena R, Crawford JM, et al. Utilization of acidophil bodies in the diagnosis of recurrent hepatitis C infection after orthotopic liver transplantation. Mod Pathol. 2002;15:897-903.
34. Schirren CA, Jung M, et al. Cytokine profile of liver- and blood-derived nonspecific T cells after liver transplantation: T helper cells type 1/0 lymphokines dominate in recurrent hepatitis C virus infection and rejection. Liver Transpl. 2000;6:222-228.
35. Starzl TE, Demetris AJ, et al. Cell migration, chimerism, and graft acceptance. Lancet. 1992;339:1579-1582.
36. Starzl TE, Murase N, et al. Tolerogenic immunosuppression for organ transplantation. Lancet. 2003;361:1502-1510.
37. Starzl TE, Zinkernagel RM. Antigen localization and migration in immunity and tolerance. N Engl J Med 1998;339:1905-1913.
38. Thai NL, Fu F, et al. Cytokine mRNA profiles in mouse orthotopic liver transplantation. Graft rejection is associated with augmented TH1 function. Transplantation. 1995;59:274-281.
39. Van Kooyk Y, Geijtenbeek TB. DC-SIGN: escape mechanism for pathogens. Nat Rev Immunol. 2003;3:697-709.
40. Wiesner RH, Demetris AJ, et al. Acute hepatic allograft rejection: incidence, risk factors, and impact on outcome. Hepatology. 1998;28:638-645.
41. Wodarz D. Hepatitis C virus dynamics and pathology: the role of CTL and antibody responses. J Gen Virol. 2003;84:1743-1750.
42. Zekry A, Bishop GA, et al. Intrahepatic cytokine profiles associated with posttransplantation hepatitis C virus-related liver injury. Liver Transpl. 2002;8:292-301.